Current
Treatments

for systemic sclerosis don't
address underlying drivers

MORE INDICATED TREATMENTS ARE NEEDED

Current treatments address the clinical manifestations of systemic sclerosis (SSc) as they arise, not the underlying mechanisms that drive inflammation and fibrosis. This leaves a significant unmet need and burden on patients.1-3

Not an actual patient.

Prescription bottle icon

MANY MANIFESTATIONS,
FEW SOLUTIONS

One therapy is approved for slowing the rate of decline in pulmonary function in patients with SSc-associated interstitial lung disease (SSc-ILD). Currently, there is no therapy approved in SSc beyond this manifestation.4,5

Venn diagram indicating the intersection of inflammation and fibrosis

TREATMENTS ADDRESS INFLAMMATION OR FIBROSIS,
NOT BOTH

Current approaches using immunosuppressive or antifibrotic agents only address specific symptoms. As a result, multiple therapies are often required.1,3

MANY MANIFESTATIONS,
YET FEW SOLUTIONS1,4,5

The overall health burden on patients may increase with the use of multiple
therapies used to manage individual
SSc manifestations.*3,6

*Example treatment lists are not all-inclusive.
Hand icon

SKIN

Scleroderma

EXAMPLE TREATMENTS

Immunosuppressive therapies
(e.g. methotrexate)

Pulmonary icon

PULMONARY

Interstitial lung disease (ILD)
Pulmonary arterial hypertension (PAH)

EXAMPLE TREATMENTS

Tyrosine kinase inhibitors
Immunosuppressive treatment
(e.g. mycophenolate mofetil, cyclophosphamide)
Endothelin receptor antagonists
Phosphodiesterase 5 inhibitors
Prostacyclin analogs
Soluble guanylate cyclase agonists

Heart icon

CARDIOVASCULAR

Heart failure
Inflammatory cardiac disease

EXAMPLE TREATMENTS

Drug therapies
(e.g. angiotensin-converting enzyme
inhibitors and diuretics)
Immunosuppressive therapies
(e.g. corticosteroids and/or
cyclophosphamide)

Vascular icon

PERIPHERAL VASCULAR

Raynaud’s phenomenon, digital ulcers,
and critical ischemias

EXAMPLE TREATMENTS

Calcium channel blockers
Phosphodiesterase 5 inhibitors
Angiotensin II receptor blockers
Endothelin receptor agonists

Renal icon

RENAL

Scleroderma renal crisis

EXAMPLE TREATMENTS

Angiotensin-converting
enzyme inhibitors

Gastrointestinal icon

GASTROINTESTINAL

Gastroesophageal reflux disease (GERD)

EXAMPLE TREATMENTS

Lifestyle modifications
Proton-pump inhibitors

Musculoskeletal icon

MUSCULOSKELETAL

Inflammatory arthritis

EXAMPLE TREATMENTS

Immunosuppressive therapies
(e.g. methotrexate)

DESPITE THESE SYMPTOM-SPECIFIC TREATMENTS, DISEASE BURDEN IS STILL HIGH

While treatment outcomes in SSc have improved over the last few decades, patients still face high mortality risk, especially in the diffuse population.7-9 There are a wide range of symptom-specific treatments available, however they can impose a significant health burden
on patients.5-10

POTENTIAL COMPLICATIONS FROM
SYMPTOM-SPECIFIC THERAPIES5,6,10

Thermometer icon

WEAKENED IMMUNE SYSTEM

  • Increases the risk of opportunistic infections and malignancies11
Liver icon

HIGH RISK OF GASTROINTESTINAL
AND LIVER TOXICITY

  • With potential serious adverse events6
Upward arrow icon

INCREASED CUMULATIVE BURDEN

  • With increasing number of therapies used6
Plants and greenery